These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 15863209)

  • 1. Rituximab therapy of lymphoma is enhanced by orally administered (1-->3),(1-->4)-D-beta-glucan.
    Modak S; Koehne G; Vickers A; O'Reilly RJ; Cheung NK
    Leuk Res; 2005 Jun; 29(6):679-83. PubMed ID: 15863209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies.
    Cheung NK; Modak S; Vickers A; Knuckles B
    Cancer Immunol Immunother; 2002 Nov; 51(10):557-64. PubMed ID: 12384807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor basis of biological activity of polysaccharides.
    Generalov E; Yakovenko L
    Biophys Rev; 2023 Oct; 15(5):1209-1222. PubMed ID: 37975017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From Cancer Therapy to Winemaking: The Molecular Structure and Applications of β-Glucans and β-1, 3-Glucanases.
    Caseiro C; Dias JNR; de Andrade Fontes CMG; Bule P
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I Trial of Oral Yeast-Derived β-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk Neuroblastoma.
    Cardenas FI; Mauguen A; Cheung IY; Kramer K; Kushner BH; Ragupathi G; Cheung NV; Modak S
    Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CLEC10A is a prognostic biomarker and correlated with clinical pathologic features and immune infiltrates in lung adenocarcinoma.
    He M; Han Y; Cai C; Liu P; Chen Y; Shen H; Xu X; Zeng S
    J Cell Mol Med; 2021 Apr; 25(7):3391-3399. PubMed ID: 33655701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression.
    Cheung IY; Cheung NV; Modak S; Mauguen A; Feng Y; Basu E; Roberts SS; Ragupathi G; Kushner BH
    J Clin Oncol; 2021 Jan; 39(3):215-226. PubMed ID: 33326254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing Tumor Microenvironment for Cancer Immunotherapy: β-Glucan-Based Nanoparticles.
    Zhang M; Kim JA; Huang AY
    Front Immunol; 2018; 9():341. PubMed ID: 29535722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-Type Lectin-Like Receptors As Emerging Orchestrators of Sterile Inflammation Represent Potential Therapeutic Targets.
    Chiffoleau E
    Front Immunol; 2018; 9():227. PubMed ID: 29497419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting C-Type Lectin Receptors for Cancer Immunity.
    Yan H; Kamiya T; Suabjakyong P; Tsuji NM
    Front Immunol; 2015; 6():408. PubMed ID: 26379663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accelerated tumor growth mediated by sublytic levels of antibody-induced complement activation is associated with activation of the PI3K/AKT survival pathway.
    Wu X; Ragupathi G; Panageas K; Hong F; Livingston PO
    Clin Cancer Res; 2013 Sep; 19(17):4728-39. PubMed ID: 23833306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-
    Modak S; Kushner BH; Kramer K; Vickers A; Cheung IY; Cheung NK
    Oncoimmunology; 2013 Mar; 2(3):e23402. PubMed ID: 23802080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunostimulatory properties and antitumor activities of glucans (Review).
    Vannucci L; Krizan J; Sima P; Stakheev D; Caja F; Rajsiglova L; Horak V; Saieh M
    Int J Oncol; 2013 Aug; 43(2):357-64. PubMed ID: 23739801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of lentinan for treating gastric cancer.
    Ina K; Kataoka T; Ando T
    Anticancer Agents Med Chem; 2013 Jun; 13(5):681-8. PubMed ID: 23092289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Up-regulation of GITRL on dendritic cells by WGP improves anti-tumor immunity in murine Lewis lung carcinoma.
    Tian J; Ma J; Ma K; Ma B; Tang X; Baidoo SE; Tong J; Yan J; Lu L; Xu H; Wang S
    PLoS One; 2012; 7(10):e46936. PubMed ID: 23077535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulatory dietary polysaccharides: a systematic review of the literature.
    Ramberg JE; Nelson ED; Sinnott RA
    Nutr J; 2010 Nov; 9():54. PubMed ID: 21087484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orally administered particulate beta-glucan modulates tumor-capturing dendritic cells and improves antitumor T-cell responses in cancer.
    Li B; Cai Y; Qi C; Hansen R; Ding C; Mitchell TC; Yan J
    Clin Cancer Res; 2010 Nov; 16(21):5153-64. PubMed ID: 20855461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of beta-glucan on human immune and cancer cells.
    Chan GC; Chan WK; Sze DM
    J Hematol Oncol; 2009 Jun; 2():25. PubMed ID: 19515245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined yeast-derived beta-glucan with anti-tumor monoclonal antibody for cancer immunotherapy.
    Liu J; Gunn L; Hansen R; Yan J
    Exp Mol Pathol; 2009 Jun; 86(3):208-14. PubMed ID: 19454271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer therapeutic antibodies come of age: targeting minimal residual disease.
    Ben-Kasus T; Schechter B; Sela M; Yarden Y
    Mol Oncol; 2007 Jun; 1(1):42-54. PubMed ID: 19383286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.